triage). The goal of this study is to determine factors associated with variability in the assessment and treatment of SCD patients presenting to the ED with acute pain.
Study Objectives: Flank pain secondary to renal colic is a common presentation to emergency departments (ED). Pain control for this malady varies widely, including the use of NSAID and opioid medications, the latter of which evoke several potential side effects and ethical considerations given the current national opioid epidemic. Emergency physicians are among the leaders in health care in recognizing and confronting the opioid epidemic, from acknowledgement of the problem to advocating for naloxone, PDMPs, and medication-assisted treatment. The Alternatives to Opiates (ALTO) program of St. Joseph's University Medical Center, for example, aims to mitigate the unnecessary use of opioids by providing a range of existing and innovative protocols for pain management. The primary study objective is to compare the analgesic efficacy of IV lidocaine to IV ketorolac for patients with known or suspected renal colic evaluated in a suburban tertiary medical center ED. We present an interim safety analysis as the protocol is halfway completed and still blinded, with enrollment of 30 out of a proposed 60 patients.
Methods: This is a prospective randomized double-blind cohort study. Patients are randomized by the inpatient pharmacy service to 2 groups: Group I receives acetaminophen 975 mg orally plus lidocaine 1.5 mg/kg via IV in 100 mL NS over 10 minutes while Group II receives acetaminophen 975 mg orally plus ketorolac 30 mg IV in 100 mL NS over 10 minutes. Primary study outcome is pain level using the 0-10 numeric rating scale measured at time 0 and at 5, 10, 15 and 30 minutes after medication administration. We set our goal sample size at 60 patients after determining a minimum of 50 patients with an alpha of 5% and difference of 6 units of change between treatments as the expected clinically significant change.
Results: With the blinded nature of the study protocol preserved, an interim safety analysis revealed that 7 of the 30 patients required rescue analgesia. None of the 30 patients experienced adverse effects from the medications administered.
Conclusions: An interim analysis revealed that 7 of 30 patients required rescue analgesia and none experienced any adverse effects from the medications received. Although a limited sample size, our study data suggests that IV lidocaine may be a reasonable alternative analgesic to opioids for the treatment of flank pain secondary to known or suspected renal colic, and with little increased risk of adverse medication effect.
NOTE: The views expressed are those of the author(s) and do not reflect the official policy of the Department of the Army, the Department of Defense or the U.S. Government.
Effectiveness and Safety of Droperidol in an Emergency Department in United States
Gaw CM, Cabrera D, Bellolio M, Mattson AE, Jeffery MM/Mayo Clinic, Rochester, MN Study Objectives: Droperidol is a dopamine D2 receptor antagonist, antipsychotic used extensively by emergency physicians, psychiatrists and anesthesiologists worldwide since 1967. It is an inexpensive, rapid-acting medication with a short half-life that functions as an analgesic, sedative, and antiemetic. It has been used for the treatment of headache, nausea, agitation, acute pain, chronic pain, pain in opiate-tolerance and multidrug-resistant abdominal pain. The United States Food and Drug Administration (FDA) issued a black box warning on the use of droperidol due to concerns of QT prolongation and potential fatal arrhythmias in 2001 after few case reports. Despite this, studies have found data supporting safe usage of low doses of droperidol, and its effectiveness in treating acute migraine headaches in the emergency department (ED) as well for sedation. The aim of this study was to evaluate the efficacy and safety of droperidol as an analgesic, antiemetic and sedative in a large cohort of patients presenting to the ED.
Methods: This was an observational cohort study of all droperidol administrations from 1/1/2012 through 4/19/2018 at an academic adult and pediatric ED with 77,000 annual ED visits located in United States. The primary endpoint was mortality within 24 hours of droperidol administration. Secondary endpoints included use of additional analgesia after the use of droperidol, called "rescue analgesia." We collected data on patient's date of visit, age, current medications, date and time of droperidol administration, any other medications administered in the same ED visit, chief complaint and final diagnosis. All patients who received droperidol were evaluated for the mortality and safety data. Among the patients who received droperidol for analgesia, we quantified those who required rescue analgesia 30 to 60 minutes after the
